BR112018016346A2 - processo - Google Patents

processo

Info

Publication number
BR112018016346A2
BR112018016346A2 BR112018016346A BR112018016346A BR112018016346A2 BR 112018016346 A2 BR112018016346 A2 BR 112018016346A2 BR 112018016346 A BR112018016346 A BR 112018016346A BR 112018016346 A BR112018016346 A BR 112018016346A BR 112018016346 A2 BR112018016346 A2 BR 112018016346A2
Authority
BR
Brazil
Prior art keywords
neosaxitoxin
analogs
variants
production
intermediates
Prior art date
Application number
BR112018016346A
Other languages
English (en)
Inventor
Neilan Brett
Kellmann Ralf
Original Assignee
Bergen Teknologioverfoering As
Newsouth Innovations Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bergen Teknologioverfoering As, Newsouth Innovations Pty Ltd filed Critical Bergen Teknologioverfoering As
Publication of BR112018016346A2 publication Critical patent/BR112018016346A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/182—Heterocyclic compounds containing nitrogen atoms as the only ring heteroatoms in the condensed system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/10—Nitrogen as only ring hetero atom
    • C12P17/12—Nitrogen as only ring hetero atom containing a six-membered hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1288—Transferases for other substituted phosphate groups (2.7.8)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/42—Organic phosphate, e.g. beta glycerophosphate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/185—Escherichia
    • C12R2001/19—Escherichia coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/08—Transferases for other substituted phosphate groups (2.7.8)
    • C12Y207/08007—Holo-[acyl-carrier-protein] synthase (2.7.8.7)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

a presente invenção refere-se a processos para fabricar neosaxitoxina, e análogos e variantes da mesma, e intermediários na produção de neosaxitoxina em células hospedeiras recombinantes. neosaxitoxina e os análogos e variantes da mesma podem ser usados na produção de composições farmacêuticas.
BR112018016346A 2016-02-12 2017-02-10 processo BR112018016346A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1602576.9A GB201602576D0 (en) 2016-02-12 2016-02-12 Process
PCT/EP2017/053077 WO2017137606A1 (en) 2016-02-12 2017-02-10 Process

Publications (1)

Publication Number Publication Date
BR112018016346A2 true BR112018016346A2 (pt) 2019-01-22

Family

ID=55697646

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018016346A BR112018016346A2 (pt) 2016-02-12 2017-02-10 processo

Country Status (14)

Country Link
US (2) US10920256B2 (pt)
EP (2) EP3414334B1 (pt)
JP (1) JP2019504650A (pt)
KR (1) KR20190006478A (pt)
CN (1) CN109790558A (pt)
AU (2) AU2017218598B2 (pt)
BR (1) BR112018016346A2 (pt)
CA (1) CA3014109A1 (pt)
CL (1) CL2018002149A1 (pt)
EA (1) EA201891805A1 (pt)
GB (3) GB201602576D0 (pt)
IL (1) IL261106A (pt)
MX (1) MX2018009676A (pt)
WO (1) WO2017137606A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109097415A (zh) * 2018-08-08 2018-12-28 浙江海洋大学 一种利用产毒海洋亚硫酸杆菌发酵制备石房蛤毒素的方法
US20230145895A1 (en) * 2020-03-26 2023-05-11 The Cawthron Institute Trust Board Preparation of neosaxitoxin
CN115466219B (zh) * 2022-07-28 2023-09-08 中国科学院天津工业生物技术研究所 一种1-[3-(2-氨基-4-乙基-1h-咪唑-5-基)丙基]胍的制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0693072B9 (en) 1993-04-08 2004-09-15 The Trustees of Columbia University in the City of New York Method for the synthesis of 4- and/or 5-(di)substituted 2-aminoimidazoles from 2-aminoimidazoles and aldehydes
AU7389098A (en) 1997-05-16 1998-12-08 Brigham And Women's Hospital Local anesthetic formulations
JP4289694B2 (ja) 1998-04-03 2009-07-01 正昭 児玉 新規のサキシトキシン誘導体およびその製造方法
CN1559007A (zh) 2000-12-12 2004-12-29 澳大利亚海洋科学研究院 致瘫痪水生有壳类动物毒素的分析
JP2003012699A (ja) 2001-07-04 2003-01-15 Japan Science & Technology Corp 抗麻酔性貝毒抗体の製法、新規抗体、該抗体を用いるｅｌｉｓａ測定キット、該製法による系標識毒標品
CA2466697C (en) 2001-11-15 2013-09-24 Micro Algae Corporation Pharmaceutical compositions containing 3,4-propinoperhydropurines and uses thereof for blocking neuronal transmission
US20030148359A1 (en) 2002-01-11 2003-08-07 Yale University Saxitoxin detection and assay method
AU2003901897A0 (en) 2003-02-12 2003-05-08 Australian Institute Of Marine Science Conjugate
WO2006032481A1 (en) 2004-09-21 2006-03-30 Laboratorios Del Dr. Esteve S.A. Tetrodotoxin and its derivatives for the treatment of central-nervously derived neuropathic pain
AU2005287580A1 (en) 2004-09-22 2006-03-30 Wex Medical Limited Tetrodotoxin and its derivatives for the treatment of peripheral-nervously derived neuropathic pain
RU2277097C1 (ru) 2004-12-27 2006-05-27 Институт Молекулярной Генетики Российской Академии Наук (Имг Ран) Высокомеченный тритием дигидрохлорид [3h]сакситоксина
EP1853268A1 (en) * 2005-02-11 2007-11-14 Wex Pharmaceuticals Inc. Use of sodium channel blockers and their analogues for the treatment of nicotine dependency
WO2007025212A2 (en) 2005-08-25 2007-03-01 Wex Pharmaceuticals, Inc. Use of sodium channel blockers for the treatment of visceral pain or pain caused by cancer treatment
US20100048592A1 (en) 2005-08-25 2010-02-25 Wex Pharmaceuticals Inc. Use of sodium channel blockers for the management of musculoskeletal pain
EP1844781A1 (en) 2006-02-22 2007-10-17 Wex Pharmaceuticals Inc. Use of sodium channel blockers for the treatment of preterm labor
EP1844782A1 (en) 2006-03-27 2007-10-17 Wex Pharmaceuticals, Inc Use of 4,9-anhydro-tetrodotoxin for the treatment of diseases related to the voltage-gated sodium channel subunit Nav1.6
CA2647235C (en) 2006-03-27 2019-03-12 Wex Pharmaceuticals Inc. Use of sodium channel blockers for the treatment of neuropathic pain developing as a consequence of chemotherapy
CN101903530A (zh) * 2007-10-12 2010-12-01 加利福尼亚大学董事会 被改造以产生异丙醇的微生物
DK2279265T3 (da) 2008-04-24 2014-12-08 Newsouth Innovations Pty Ltd Cyanobakterie-saxitoxin-gencluster og detektering af cyanotoksiske organismer
US8957207B2 (en) * 2009-03-24 2015-02-17 Proteus S.A. Methods for producing phycotoxins
CL2009000723A1 (es) 2009-03-24 2009-06-19 Proteus Sa Metodo de purificacion industrial de ficotoxinas biologicamente activas que comprende proporcionar una cantidad adecuada de una fuente de ficotoxinas como por ejemplo el cultivo de un clon de cianobacterias.
CN102459273A (zh) 2009-05-07 2012-05-16 里兰斯坦福初级大学理事会 用于研究、成像以及治疗疼痛的方法和组合物
WO2011094367A1 (en) 2010-01-26 2011-08-04 Evans Michael A Methods, devices, and agents for denervation
WO2011098539A1 (en) 2010-02-10 2011-08-18 Phytotox Limited Treatment of loss of sense of touch with saxitoxin derivatives
SG194948A1 (en) 2011-05-16 2013-12-30 Newsouth Innovations Pty Ltd Detection of saxitoxin-producing dinoflagellates
EP2638908A1 (en) 2012-03-16 2013-09-18 Phytotox SpA Paralytic Shellfish Poison
US9408846B2 (en) 2012-04-23 2016-08-09 The Children's Medical Center Corporation Formulations and methods for delaying onset of chronic neuropathic pain
WO2014168721A2 (en) 2013-04-12 2014-10-16 Tufts Medical Center Methods and systems for designing and/or characterizing soluble lipidated ligand agents
EP3129381B1 (en) 2014-04-09 2020-11-04 Siteone Therapeutics Inc. 10',11'-modified saxitoxins useful for the treatment of pain

Also Published As

Publication number Publication date
GB201903649D0 (en) 2019-05-01
MX2018009676A (es) 2019-06-06
EP3414334C0 (en) 2023-10-11
US20210108239A1 (en) 2021-04-15
KR20190006478A (ko) 2019-01-18
WO2017137606A1 (en) 2017-08-17
EP4279577A3 (en) 2024-01-24
CA3014109A1 (en) 2017-08-17
EP3414334B1 (en) 2023-10-11
AU2017218598B2 (en) 2021-05-06
EA201891805A1 (ru) 2019-02-28
GB2569907A (en) 2019-07-03
CL2018002149A1 (es) 2019-02-15
JP2019504650A (ja) 2019-02-21
GB201702275D0 (en) 2017-03-29
GB2552859A (en) 2018-02-14
AU2021201969A1 (en) 2021-04-29
GB2552859B (en) 2019-09-18
GB2569907B (en) 2020-04-08
AU2021201969B2 (en) 2023-02-02
US10920256B2 (en) 2021-02-16
EP3414334A1 (en) 2018-12-19
AU2017218598A1 (en) 2018-10-04
US20190048375A1 (en) 2019-02-14
EP4279577A2 (en) 2023-11-22
IL261106A (en) 2018-10-31
US11566271B2 (en) 2023-01-31
CN109790558A (zh) 2019-05-21
GB201602576D0 (en) 2016-03-30

Similar Documents

Publication Publication Date Title
BR112016017261A8 (pt) composto, composição farmacêutica, uso de um composto e processo para a fabricação de um composto
BR112017007123A2 (pt) derivados de tetrahidroisoquinolina
BR112018007017A2 (pt) polipeptídeos
BR112017027414A2 (pt) Derivados hidroxiéster, processo para prepará- los e composições farmacêuticas os contendo
BR112017023740A2 (pt) ?forma sólida de um composto, processo para a preparação de uma forma sólida, composição farmacêutica, método para o tratamento ou prevenção de doenças e utilização de uma forma sólida?
BR112018076126A2 (pt) compostos heterocíclicos como antibacterianos
BR112017027831A2 (pt) derivados de hidroxiácido, um processo para sua preparação e composições farmacêuticas contendo-os
BR112016025132A2 (pt) compostos polifluorados agindo como inibidores de tirosina quinase de bruton
BR112018075939A2 (pt) compostos heterocíclicos como antibacterianos
CO2017006174A2 (es) Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de desórdenes inflamatorios y oesteoartritis
BR112017028322A2 (pt) compostos, processo para a produção de compostos i, para a produção de compostos ii dos compostos iii e para a produção de compostos iii, compostos intermediários v e utilização dos compostos i
UY36178A (es) Novedosos derivados de ácido heteroaril-butanoico
BR112019003437A2 (pt) processo para a fabricação de uma forma de administração farmacêutica sólida
BR112017005109A2 (pt) produto refratário com base em al2o3, composição de matérias-primas para a fabricação do produto, método para a fabricação de um produto refratário, produto refratário, e emprego do produto refratário
BR112017019850A2 (pt) ?processo melhorado para a preparação de apremilast?
BR112016028316A2 (pt) composição farmacêutica oral de isotretinoina, seu processo de preparação e método de tratamento
BR112018016346A2 (pt) processo
BR112017001847A2 (pt) processo para a preparação de um composto de fórmula (i), mistura, composição e composto de fórmula (ii)
BR112017018993A2 (pt) Processo para preparar 3-cloro-2- vinilfenilassulfonatos
BR112018007394A2 (pt) processo para produzir uma suspensão aquosa de carbonato de cálcio precipitado, suspensão aquosa de carbonato de cálcio precipitado, produto, carbonato de cálcio precipitado, e, uso de uma suspensão aquosa de carbonato de cálcio precipitado
BR112018012193A2 (pt) variantes do polipeptídeo de fusão relacionados à ômega-hidroxilase com propriedades melhoradas
BR112018069782A2 (pt) composição farmacêutica de dapagliflozina
BR112018013079A2 (pt) cepas mutantes de trichoderma reesei
BR112016028083A2 (pt) Composição oral farmacêutica de isotretinoina e seu processo de preparação
BR112016027819A8 (pt) processo de preparação de derivados de tiazole

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements